FDA advisors overwhelmingly endorse Novavax COVID-19 vaccine

Empty vials of the Novavax Inc. Nuvaxovid COVID-19 vaccine arranged at the Tegel Vaccine Center in Berlin, Germany, on Monday, March 7, 2022.

Enlarge / Empty vials of the Novavax Inc. Nuvaxovid COVID-19 vaccine organized on the Tegel Vaccine Middle in Berlin, Germany, on Monday, March 7, 2022. (credit score: Getty | Bloomberg )

A committee of impartial, knowledgeable advisors for the Meals and Drug Administration voted overwhelmingly in favor of authorizing the two-dose Novavax COVID-19 vaccine Tuesday, with 21 of 22 committee members voting in favor of the vaccine and one member abstaining.

The endorsement is just for a two-dose main sequence in adults, not for boosters. The FDA isn’t obligated to comply with the recommendation of its committee—the Vaccines and Associated Organic Merchandise Advisory Committee (VRBPAC)—however the company sometimes heeds its recommendation. If the FDA authorizes the vaccine, the Facilities for Illness Management and Prevention might want to log off on use earlier than it turns into obtainable.

The choice concerning the Novavax vaccine, which is already approved in dozens of different nations, isn’t an easy one within the US. The vaccine has some benefits over presently used vaccines however has a number of strikes in opposition to it.

Learn 12 remaining paragraphs | Feedback